Acadia Pharmaceuticals Inc ACAD
Acadia Pharmaceuticals Inc (Nasdaq: ACAD) is a CNS/neurology/psychiatry drug developer. Its lead program, remlifanserin (ACP-204), is in Phase 3 for hallucinations and delusions associated with Alzheimer's disease psychosis (ADP); also Lewy Body Dementia Psychosis. Its next catalyst on record is Remlifanserin: Detailed Phase 2 RADIANT results to be presented at CTAD conference in November 2026. (November 2026).
Upcoming catalysts
- November 2026Remlifanserin — Detailed Phase 2 RADIANT results to be presented at CTAD conference in November 2026.
Acadia plans to present detailed safety and efficacy results from the RADIANT Phase 2 study in an oral presentation at the upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place November 16-19, 2026 in Boston.
Next further out: ACP-211 — Phase 2 MDD topline results (2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| remlifanserin (RADIANT Phase 2/3) | Alzheimer's disease psychosis | small molecule | Phase 3 |
| remlifanserin (ILLUMERA) | Lewy Body Dementia Psychosis | small molecule | Phase 2 |
| ACP-211 | major depressive disorder | small molecule | Phase 2 |
| ACP-2591 | Rett syndrome / Fragile X syndrome | small molecule | Phase 1 |
| ACP-271 | tardive dyskinesia / Huntington's disease | small molecule | Phase 1 |
| ACP-711 | essential tremor | small molecule | Phase 1 |
Recent results and decisions
- Sep 24, 2026missed Phase 2 RADIANT narrowly missed primary endpoint SAPS-H+D at 60 mg (-12.6 vs -10.4 placebo, p=0.0603); key secondary CGI-S-ADP nominal p=0.0077; Phase 3 to continue with 30 mg arm removed.
Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077)
Filing - Sep 24, 2026mixed Remlifanserin 60 mg narrowly missed primary endpoint SAPS H+D (p=0.0603) but achieved nominal significance on key secondary endpoint CGI-S-ADP (p=0.0077) in Phase 2 RADIANT study.
Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077)
Filing - Aug 4, 2026completed enrollment Completed enrollment in the Phase 2 portion of RADIANT and initiated Phase 3 screening and enrollment.
Completed enrollment in the Phase 2 portion of the RADIANT program evaluating remlifanserin in Alzheimer's disease psychosis and initiated Phase 3 screening and enrollment; topline Phase 2 results are expected in September to October 2026.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.